NCT00060515

Brief Summary

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Trial Health

10
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_1

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2003

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 8, 2003

Completed
Last Updated

August 5, 2005

Status Verified

August 1, 2005

First QC Date

May 7, 2003

Last Update Submit

August 4, 2005

Conditions

Mitochondrial Diseases

Interventions

RG2133 (2',3',5'-tri-O-acetyluridine)DRUG

Eligibility Criteria

Age3 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Mitochondrial Disease

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

MeSH Terms

Conditions

Mitochondrial Diseases

Interventions

uridine triacetate

Condition Hierarchy (Ancestors)

Metabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 7, 2003

First Posted

May 8, 2003

Last Updated

August 5, 2005

Record last verified: 2005-08